Randomized control trial of secondary eradication therapies of Helicobacter pylori

Randomized control trial of secondary eradication therapies of Helicobacter pylori - Secondary eradication therapies of Helicobacter

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003074

Enrollment

180

Registered

2010-01-21

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroduodenal ulcer infected by Helicobacter pylori

Interventions

rabeprazole 10mg bid, amoxicillin 750mg bid and metronidazole 250mg bid lansorazole 10mg bid, amoxicillin 750mg bid and metronidazole 250mg bid omeprazole 10mg bid, amoxicillin 750mg bid and metronid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who fills everything the following 1)Patients with gastric or duodenal ulcer 2)Patients of primary eradication failure 3)Patients infected by Helicobacter pylori, confirmed by bacterial culture test or rapid urease test or urea breath test 4)Patients of 20 years or more 5)Patients who gives written informed consent

Exclusion criteria

Exclusion criteria: 1)Pregnant females 2)Lacting woman 3)Patients who has past history of allergy for the drugs used in this study 4)Patients who has coexisting severe disease 5)Patient whom examination doctor judged improper as testee

Design outcomes

Primary

Measure	Time frame
Assessment of the Helicobacter pylori eradication on the bassis of the urea breath test result	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026